The high CR rate of 87.5% in patients with double-expressor (BCL2+ MYC+) DLBCL was a particularly promising finding, and venetoclax plus R-CHOP is currently being evaluated in patients with newly diagnosed DLBCL in the phase 2 portion of the study [76]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.